Chang Yoon Doh

Chang Yoon Doh

Auto-generated profile, based on publicly available information

Chang Yoon Doh

Department of Internal Medicine Oregon Health & Science University Portland Oregon USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
RMRanganath Mamidi
Ranganath Mamidi
JLJiayang Li
Jiayang Li
CDChang Yoon Doh
Chang Yoon Doh
SVSujeet Verma
Sujeet Verma
JSJulian E. Stelzer
Julian E. Stelzer
Background: Recent studies suggest that mavacamten (Myk461), a small myosin‐binding molecule, decreases hypercontractility in myocardium expressing hypertrophic cardiomyopathy‐causing missense mutations in myosin heavy chain. However, the predominant feature of most mutations in cardiac myosin binding protein‐C ( cMyBPC ) that cause hypertrophic cardiomyopathy is reduced total cMyBPC expression, and the impact of Myk461 on cMyBPC ‐deficient myocardium is currently unknown. Methods and Results: We measured the impact of Myk461 on steady‐state and dynamic cross‐bridge ( XB ) behavior in detergent‐skinned mouse wild‐type myocardium and myocardium lacking cMyBPC (knockout (KO)). KO myocardium exhibited hypercontractile XB behavior as indicated by significant accelerations in rates of XB detachment (k rel ) and recruitment (k df ) at submaximal Ca 2+ activations. Incubation of KO and wild‐type myocardium with Myk461 resulted in a dose‐dependent force depression, and this impact was more pronounced at low Ca 2+ activations. Interestingly, Myk461‐induced force depressions were less pronounced in KO myocardium, especially at low Ca 2+ activations, which may be because of increased acto‐myosin XB formation and potential disruption of super‐relaxed XB s in KO myocardium. Additionally, Myk461 slowed k rel in KO myocardium but not in wild‐type myocardium, indicating increased XB “ on ” time. Furthermore, the greater degree of Myk461‐induced slowing in k df and reduction in XB recruitment magnitude in KO myocardium normalized the XB behavior back to wild‐type levels. Conclusions: This is the first study to demonstrate that Myk461‐induced force depressions are modulated by cMyBPC expression levels in the sarcomere, and emphasizes that clinical use of Myk461 may need to be optimized based on the molecular trigger that underlies the hypertrophic cardiomyopathy phenotype.

1 October 2017 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
RMRanganath Mamidi
Ranganath Mamidi
JLJiayang Li
Jiayang Li
KGKenneth S. Gresham
Kenneth S. Gresham
SVSujeet Verma
Sujeet Verma
CDChang Yoon Doh
Chang Yoon Doh
JSJulian E. Stelzer
Julian E. Stelzer
Background: Omecamtiv mecarbil (OM) enhances systolic function in vivo by directly binding the myosin cross-bridges (XBs) in the sarcomere. However, the mechanistic details governing OM-induced modulation of XB behavior in failing human myocardium are unclear. Methods and Results: The effects of OM on steady state and dynamic XB behavior were measured in chemically skinned myocardial preparations isolated from human donor and heart failure (HF) left ventricle. HF myocardium exhibited impaired contractile function as evidenced by reduced maximal force, magnitude of XB recruitment ( P df ), and a slowed rate of XB detachment ( k rel ) at submaximal Ca 2+ activations. Ca 2+ sensitivity of force generation (pCa 50 ) was higher in HF myocardium when compared with donor myocardium, both prior to and after OM incubations. OM incubation (0.5 and 1.0 μmol/L) enhanced force generation at submaximal Ca 2+ activations in a dose-dependent manner. Notably, OM induced a slowing in k rel with 1.0 μmol/L OM but not with 0.5 μmol/L OM in HF myocardium. Additionally, OM exerted other differential effects on XB behavior in HF myocardium as evidenced by a greater enhancement in P df and slowing in the time course of cooperative XB recruitment ( T rec ), which collectively prolonged achievement of peak force development ( T pk ), compared with donor myocardium. Conclusions: Our findings demonstrate that OM augments force generation but also prolongs the time course of XB transitions to force-bearing states in remodeled HF myocardium, which may extend the systolic ejection time in vivo. Optimal OM dosing is critical for eliciting enhanced systolic function without excessive prolongation of systolic ejection time, which may compromise diastolic filling.

3 September 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JLJiayang Li
Jiayang Li
RMRanganath Mamidi
Ranganath Mamidi
CDChang Yoon Doh
Chang Yoon Doh
JHJoshua B. Holmes
Joshua B. Holmes
NBNikhil Bharambe
Nikhil Bharambe
JSJulian E. Stelzer
Julian E. Stelzer
Decreased cardiac myosin-binding protein C (cMyBPC) expression due to inheritable mutations is thought to contribute to the hypertrophic cardiomyopathy (HCM) phenotype, suggesting that increasing cMyBPC content is of therapeutic benefit. In vitro assays show that cMyBPC N-terminal domains (NTDs) contain structural elements necessary and sufficient to modulate actomyosin interactions, but it is unknown if they can regulate in vivo myocardial function. To test whether NTDs can recapitulate the effects of full-length (FL) cMyBPC in rescuing cardiac function in a cMyBPC-null mouse model of HCM, we assessed the efficacy of AAV9 gene transfer of a cMyBPC NTD that contained domains C0C2 and compared its therapeutic potential with AAV9-FL gene replacement. AAV9 vectors were administered systemically at neonatal day 1, when early-onset disease phenotypes begin to manifest. A comprehensive analysis of in vivo and in vitro function was performed following cMyBPC gene transfer. Our results show that a systemic injection of AAV9-C0C2 significantly improved cardiac function (e.g., 52.24 ± 1.69 ejection fraction in the C0C2-treated group compared with 40.07 ± 1.97 in the control cMyBPC –/– group, P < 0.05) and reduced the histopathologic signs of cardiomyopathy. Furthermore, C0C2 significantly slowed and normalized the accelerated cross-bridge kinetics found in cMyBPC –/– control myocardium, as evidenced by a 32.41% decrease in the rate of cross-bridge detachment ( k rel ). Results indicate that C0C2 can rescue biomechanical defects of cMyBPC deficiency and that the NTD may be a target region for therapeutic myofilament kinetic manipulation.

1 March 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
CDChang Yoon Doh
Chang Yoon Doh
JLJiayang Li
Jiayang Li
RMRanganath Mamidi
Ranganath Mamidi
JSJulian E. Stelzer
Julian E. Stelzer

1 December 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
JLJiayang Li
Jiayang Li
KGKenneth S. Gresham
Kenneth S. Gresham
RMRanganath Mamidi
Ranganath Mamidi
CDChang Yoon Doh
Chang Yoon Doh
XWXiaoping Wan
Xiaoping Wan
JSJulian E. Stelzer
Julian E. Stelzer

10 March 2021 in Journal of General Physiology
Verified
Journal Article
Open access
PDF file
RMRanganath Mamidi
Ranganath Mamidi
JHJoshua B. Holmes
Joshua B. Holmes
CDChang Yoon Doh
Chang Yoon Doh
KDKatherine L. Dominic
Katherine L. Dominic
NMNikhil Madugula
Nikhil Madugula
JSJulian E. Stelzer
Julian E. Stelzer
Omecamtiv mecarbil (OM), a direct myosin motor activator, is currently being tested as a therapeutic replacement for conventional inotropes in heart failure (HF) patients. It is known that HF patients exhibit dysregulated β-adrenergic signaling and decreased cardiac myosin-binding protein C (cMyBPC) phosphorylation, a critical modulator of myocardial force generation. However, the functional effects of OM in conditions of altered cMyBPC phosphorylation have not been established. Here, we tested the effects of OM on force generation and cross-bridge (XB) kinetics using murine myocardial preparations isolated from wild-type (WT) hearts and from hearts expressing S273A, S282A, and S302A substitutions (SA) in the M domain, between the C1 and C2 domains of cMyBPC, which cannot be phosphorylated. At submaximal Ca2+ activations, OM-mediated force enhancements were less pronounced in SA than in WT myocardial preparations. Additionally, SA myocardial preparations lacked the dose-dependent increases in force that were observed in WT myocardial preparations. Following OM incubation, the basal differences in the rate of XB detachment (krel) between WT and SA myocardial preparations were abolished, suggesting that OM differentially affects the XB behavior when cMyBPC phosphorylation is reduced. Similarly, in myocardial preparations pretreated with protein kinase A to phosphorylate cMyBPC, incubation with OM significantly slowed krel in both the WT and SA myocardial preparations. Collectively, our data suggest there is a strong interplay between the effects of OM and XB behavior, such that it effectively uncouples the sarcomere from cMyBPC phosphorylation levels. Our findings imply that OM may significantly alter the in vivo cardiac response to β-adrenergic stimulation.